Nurix Therapeutics: Chief scientific officer Gwenn Hansen sold 1,452 shares

What happened Gwenn Hansen, chief scientific officer, exercised options that resulted in 1,452 shares acquired at $1.86 per share (cost $2,701) and sold 1,452 shares in an open-market sale at $25.00 per share (proceeds $36,300) on Oct 15, 2026. The filing also shows a related derivative disposition reported at $0.00.

Key details

• Transaction date and prices: Oct 15, 2026 — exercised 1,452 shares at $1.86 (code M) and sold 1,452 shares at $25.00 (code S); a derivative disposition reported at $0.00.
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes: F1 — sale effected pursuant to a Rule 10b5-1 trading plan; F2 — option vested 1/48 monthly beginning Jun 10, 2019 and fully vested on May 10, 2023.
• Filing timeliness: the provided report does not indicate a late filing.

Why it may matter

• The filing shows the options were exercised and the resulting shares were sold on the same date, consistent with a cashless exercise and immediate sale.
• The open-market sale was effected under a Rule 10b5-1 trading plan per the filing. A filing does not show why the insider traded or why the company acted.